A Novel DSF-Like Signal from Burkholderia Cenocepacia Interferes with Candida Albicans Morphological Transition
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Crystal Structures of the Burkholderia Multivorans Hopanoid Transporter Hpnn
Crystal structures of the Burkholderia multivorans hopanoid transporter HpnN Nitin Kumara,1, Chih-Chia Sub,1, Tsung-Han Choub, Abhijith Radhakrishnana, Jared A. Delmarb, Kanagalaghatta R. Rajashankarc,d, and Edward W. Yua,b,2 aDepartment of Chemistry, Iowa State University, Ames, IA 50011; bDepartment of Physics and Astronomy, Iowa State University, IA 50011; cNortheastern Collaborative Access Team, Argonne National Laboratory, Argonne, IL 60439; and dDepartment of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14850 Edited by Eric Gouaux, Oregon Health and Science University, Portland, OR, and approved May 15, 2017 (received for review November 30, 2016) Strains of the Burkholderia cepacia complex (Bcc) are Gram-negative critical line of defense against antimicrobial agents in Burkholderia opportunisitic bacteria that are capable of causing serious diseases, species is the permeability barrier of the outer membrane. Most of mainly in immunocompromised individuals. Bcc pathogens are in- these species contain a modified lipopolysaccharide, which results in trinsically resistant to multiple antibiotics, including β-lactams, ami- polymyxin resistance (13). In addition, the permeability of the major noglycosides, fluoroquinolones, and polymyxins. They are major outer membrane porin channel Omp38 appears to be low for an- pathogens in patients with cystic fibrosis (CF) and can cause severe tibiotics (14). The presence of a large number of multidrug efflux necrotizing pneumonia, which is often fatal. Hopanoid biosynthesis pumps, belonging to the resistance-nodulation-cell division (RND) is one of the major mechanisms involved in multiple antimicrobial superfamily, also plays a major role in the intrinsic resistance to a resistance of Bcc pathogens. The hpnN gene of B. -
Austin Ultrahealth Yeast-Free Protocol 1
1 01/16/12/ Austin UltraHealth Yeast-Free Protocol 1. Follow the Yeast Diet in your binder for 6 weeks or you may also use recipes from the Elimination Diet. (Just decrease the amount of grains and fruits allowed). 2. You will be taking one pill of prescription antifungal daily, for 30 days. This should always be taken two hours away from your probiotics. This medication can be very hard on your liver so it is important to refrain from ALL alcohol while taking this medication. Candida Die-Off Some patients experience die-off symptoms while eliminating the yeast, or Candida, in their gut. Die off symptoms can include the following: Brain fog Dizziness Headache Floaters in the eyes Anxiety/Irritability Gas, bloating and/or flatulence Diarrhea or constipation Joint/muscle pain General malaise or exhaustion What Causes Die-Off Symptoms? The Candida “die-off” occurs when excess yeast in the body literally dies off. When this occurs, the dying yeasts produce toxins at a rate too fast for your body to process and eliminate. While these toxins are not lethal to the system, they can cause an increase in the symptoms you might already have been experiencing. As the body works to detoxify, those Candida die-off symptoms can emerge and last for a matter of days, or weeks. The two main factors which cause the unpleasant symptoms of Candida die off are dietary changes and antifungal treatments, both of which you will be doing. Dietary Changes: When you begin to make healthy changes in your diet, you begin to starve the excess yeasts that have been hanging around, using up the extra sugars in your blood. -
Burkholderia Cenocepacia Integrates Cis-2-Dodecenoic Acid and Cyclic Dimeric Guanosine Monophosphate Signals to Control Virulence
Burkholderia cenocepacia integrates cis-2-dodecenoic acid and cyclic dimeric guanosine monophosphate signals to control virulence Chunxi Yanga,b,c,d,1, Chaoyu Cuia,b,c,1, Qiumian Yea,b, Jinhong Kane, Shuna Fua,b, Shihao Songa,b, Yutong Huanga,b, Fei Hec, Lian-Hui Zhanga,c, Yantao Jiaf, Yong-Gui Gaod, Caroline S. Harwoodb,g,2, and Yinyue Denga,b,c,2 aState Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, South China Agricultural University, Guangzhou 510642, China; bGuangdong Innovative Research Team of Sociomicrobiology, College of Agriculture, South China Agricultural University, Guangzhou 510642, China; cIntegrative Microbiology Research Centre, South China Agricultural University, Guangzhou 510642, China; dSchool of Biological Sciences, Nanyang Technological University, Singapore 637551; eCenter for Crop Germplasm Resources, Institute of Crop Sciences, Chinese Academy of Agricultural Sciences, Beijing 100081, China; fState Key Laboratory of Plant Genomics, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; and gDepartment of Microbiology, University of Washington, Seattle, WA 98195 Contributed by Caroline S. Harwood, October 30, 2017 (sent for review June 1, 2017; reviewed by Maxwell J. Dow and Tim Tolker-Nielsen) Quorum sensing (QS) signals are used by bacteria to regulate N-octanoyl homoserine lactone (C8-HSL). The two QS systems biological functions in response to cell population densities. Cyclic have both distinct and overlapping effects on gene expression diguanosine monophosphate (c-di-GMP) regulates cell functions in (16, 17). response to diverse environmental chemical and physical signals One of the ways in which QS systems can act is by controlling that bacteria perceive. In Burkholderia cenocepacia, the QS signal levels of intracellular cyclic diguanosine monophosphate (c-di-GMP) receptor RpfR degrades intracellular c-di-GMP when it senses the in bacteria (18–21). -
Candida Auris
microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks. -
Candida Species Identification by NAA
Candida Species Identification by NAA Background Vulvovaginal candidiasis (VVC) occurs as a result of displacement of the normal vaginal flora by species of the fungal genus Candida, predominantly Candida albicans. The usual presentation is irritation, itching, burning with urination, and thick, whitish discharge.1 VVC accounts for about 17% to 39% of vaginitis1, and most women will be diagnosed with VVC at least once during their childbearing years.2 In simplistic terms, VVC can be classified into uncomplicated or complicated presentations. Uncomplicated VVC is characterized by infrequent symptomatic episodes, mild to moderate symptoms, or C albicans infection occurring in nonpregnant and immunocompetent women.1 Complicated VVC, in contrast, is typified by severe symptoms, frequent recurrence, infection with Candida species other than C albicans, and/or occurrence during pregnancy or in women with immunosuppression or other medical conditions.1 Diagnosis and Treatment of VVC Traditional diagnosis of VVC is accomplished by either: (i) direct microscopic visualization of yeast-like cells with or without pseudohyphae; or (ii) isolation of Candida species by culture from a vaginal sample.1 Direct microscopy sensitivity is about 50%1 and does not provide a species identification, while cultures can have long turnaround times. Today, nucleic acid amplification-based (NAA) tests (eg, PCR) for Candida species can provide high-quality diagnostic information with quicker turnaround times and can also enable investigation of common potential etiologies -
Candida & Nutrition
Candida & Nutrition Presented by: Pennina Yasharpour, RDN, LDN Registered Dietitian Dickinson College Kline Annex Email: [email protected] What is Candida? • Candida is a type of yeast • Most common cause of fungal infections worldwide Candida albicans • Most common species of candida • C. albicans is part of the normal flora of the mucous membranes of the respiratory, gastrointestinal and female genital tracts. • Causes infections Candidiasis • Overgrowth of candida can cause superficial infections • Commonly known as a “yeast infection” • Mouth, skin, stomach, urinary tract, and vagina • Oropharyngeal candidiasis (thrush) • Oral infections, called oral thrush, are more common in infants, older adults, and people with weakened immune systems • Vulvovaginal candidiasis (vaginal yeast infection) • About 75% of women will get a vaginal yeast infection during their lifetime Causes of Candidiasis • Humans naturally have small amounts of Candida that live in the mouth, stomach, and vagina and don't cause any infections. • Candidiasis occurs when there's an overgrowth of the fungus RISK FACTORS WEAKENED ASSOCIATED IMUMUNE SYSTEM FACTORS • HIV/AIDS (Immunosuppression) • Infants • Diabetes • Elderly • Corticosteroid use • Antibiotic use • Contraceptives • Increased estrogen levels Type 2 Diabetes – Glucose in vaginal secretions promote Yeast growth. (overgrowth) Treatment • Antifungal medications • Oral rinses and tablets, vaginal tablets and suppositories, and creams. • For vaginal yeast infections, medications that are available over the counter include creams and suppositories, such as miconazole (Monistat), ticonazole (Vagistat), and clotrimazole (Gyne-Lotrimin). • Your doctor may prescribe a pill, fluconazole (Diflucan). The Candida Diet • Avoid carbohydrates: Supporters believe that Candida thrives on simple sugars and recommend removing them, along with low-fiber carbohydrates (eg, white bread). -
Burkholderia Cenocepacia Intracellular Activation of the Pyrin
Activation of the Pyrin Inflammasome by Intracellular Burkholderia cenocepacia Mikhail A. Gavrilin, Dalia H. A. Abdelaziz, Mahmoud Mostafa, Basant A. Abdulrahman, Jaykumar Grandhi, This information is current as Anwari Akhter, Arwa Abu Khweek, Daniel F. Aubert, of September 29, 2021. Miguel A. Valvano, Mark D. Wewers and Amal O. Amer J Immunol 2012; 188:3469-3477; Prepublished online 24 February 2012; doi: 10.4049/jimmunol.1102272 Downloaded from http://www.jimmunol.org/content/188/7/3469 Supplementary http://www.jimmunol.org/content/suppl/2012/02/24/jimmunol.110227 Material 2.DC1 http://www.jimmunol.org/ References This article cites 71 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/188/7/3469.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Activation of the Pyrin Inflammasome by Intracellular Burkholderia cenocepacia Mikhail A. -
GRAS Notice for Pichia Kudriavzevii ASCUSDY21 for Use As a Direct Fed Microbial in Dairy Cattle
GRAS Notice for Pichia kudriavzevii ASCUSDY21 for Use as a Direct Fed Microbial in Dairy Cattle Prepared for: Division of Animal Feeds, (HFV-220) Center for Veterinary Medicine 7519 Standish Place Rockville, Maryland 20855 Submitted by: ASCUS Biosciences, Inc. 6450 Lusk Blvd Suite 209 San Diego, California 92121 GRAS Notice for Pichia kudriavzevii ASCUSDY21 for Use as a Direct Fed Microbial in Dairy Cattle TABLE OF CONTENTS PART 1 – SIGNED STATEMENTS AND CERTIFICATION ................................................................................... 9 1.1 Name and Address of Organization .............................................................................................. 9 1.2 Name of the Notified Substance ................................................................................................... 9 1.3 Intended Conditions of Use .......................................................................................................... 9 1.4 Statutory Basis for the Conclusion of GRAS Status ....................................................................... 9 1.5 Premarket Exception Status .......................................................................................................... 9 1.6 Availability of Information .......................................................................................................... 10 1.7 Freedom of Information Act, 5 U.S.C. 552 .................................................................................. 10 1.8 Certification ................................................................................................................................ -
Characterization of the Burkholderia Cenocepacia J2315 Surface-Exposed Immunoproteome
Article Characterization of the Burkholderia cenocepacia J2315 Surface-Exposed Immunoproteome 1, 1, 1, Sílvia A. Sousa * , António M.M. Seixas y , Manoj Mandal y, Manuel J. Rodríguez-Ortega 2 and Jorge H. Leitão 1,* 1 iBB–Institute for Bioengineering and Biosciences, 1049-001 Lisbon, Portugal; [email protected] (A.M.M.S.); [email protected] (M.M.) 2 Departament of Biochemistry and Molecular Biology, Córdoba University, 14071 Córdoba, Spain; [email protected] * Correspondence: [email protected] (S.A.S.); [email protected] (J.H.L.); Tel.: +351-2184-19986 (S.A.S.); +351-2184-17688 (J.H.L.) Both authors contributed equally to the work. y Received: 31 July 2020; Accepted: 3 September 2020; Published: 6 September 2020 Abstract: Infections by the Burkholderia cepacia complex (Bcc) remain seriously life threatening to cystic fibrosis (CF) patients, and no effective eradication is available. A vaccine to protect patients against Bcc infections is a highly attractive therapeutic option, but none is available. A strategy combining the bioinformatics identification of putative surface-exposed proteins with an experimental approach encompassing the “shaving” of surface-exposed proteins with trypsin followed by peptide identification by liquid chromatography and mass spectrometry is here reported. The methodology allowed the bioinformatics identification of 263 potentially surface-exposed proteins, 16 of them also experimentally identified by the “shaving” approach. Of the proteins identified, 143 have a high probability of containing B-cell epitopes that are surface-exposed. The immunogenicity of three of these proteins was demonstrated using serum samples from Bcc-infected CF patients and Western blotting, validating the usefulness of this methodology in identifying potentially immunogenic surface-exposed proteins that might be used for the development of Bcc-protective vaccines. -
Vaginal Yeast Infection a Vaginal Yeast Infection Is an Infection of the Vagina, Most Commonly Due to the Fungus Candida Albicans
5285 Anthony Wayne Drive, Detroit, MI 48202 (P) 313-577-5041 | (F) 313-577-9581 health.wayne.edu Vaginal Yeast Infection A vaginal yeast infection is an infection of the vagina, most commonly due to the fungus Candida albicans. Causes, incidence, and risk factors Most women have a vaginal yeast infection at some time. Candida albicans is a common type of fungus. It is often found in small amounts in the vagina, mouth, digestive tracts, and on the skin. Usually it does not cause disease or symptoms. Candida and the many other germs that normally live in the vagina keep each other in balance. However, sometimes the number of Candida albicans increases, leading to a yeast infection. A yeast infection can happen if you are: • Taking antibiotics used to treat other types of infections. Antibiotics change the normal balance between germs in the vagina by decreasing the number of protective bacteria. • Pregnant • Obese • Have diabetes A yeast infection is not a sexually transmitted illness. However, some men will develop symptoms such as itching and a rash on the penis after having sexual contact with an infected partner. Having many vaginal yeast infections may be a sign of other health problems. Other vaginal infections and discharges can be mistaken for vaginal yeast infection. Symptoms • Pain with intercourse • Painful urination • Redness and swelling of the vulva • Vaginal and labial itching, burning • Abnormal Vaginal Discharge • Ranges from a slightly watery, white discharge to a thick, white, chunky discharge (like cottage cheese) Signs and Tests A pelvic examination will be done. It may show swelling and redness of the skin of the vulva, in the vagina, and on the cervix. -
Targeting the Burkholderia Cepacia Complex
viruses Review Advances in Phage Therapy: Targeting the Burkholderia cepacia Complex Philip Lauman and Jonathan J. Dennis * Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-780-492-2529 Abstract: The increasing prevalence and worldwide distribution of multidrug-resistant bacterial pathogens is an imminent danger to public health and threatens virtually all aspects of modern medicine. Particularly concerning, yet insufficiently addressed, are the members of the Burkholderia cepacia complex (Bcc), a group of at least twenty opportunistic, hospital-transmitted, and notoriously drug-resistant species, which infect and cause morbidity in patients who are immunocompromised and those afflicted with chronic illnesses, including cystic fibrosis (CF) and chronic granulomatous disease (CGD). One potential solution to the antimicrobial resistance crisis is phage therapy—the use of phages for the treatment of bacterial infections. Although phage therapy has a long and somewhat checkered history, an impressive volume of modern research has been amassed in the past decades to show that when applied through specific, scientifically supported treatment strategies, phage therapy is highly efficacious and is a promising avenue against drug-resistant and difficult-to-treat pathogens, such as the Bcc. In this review, we discuss the clinical significance of the Bcc, the advantages of phage therapy, and the theoretical and clinical advancements made in phage therapy in general over the past decades, and apply these concepts specifically to the nascent, but growing and rapidly developing, field of Bcc phage therapy. Keywords: Burkholderia cepacia complex (Bcc); bacteria; pathogenesis; antibiotic resistance; bacterio- phages; phages; phage therapy; phage therapy treatment strategies; Bcc phage therapy Citation: Lauman, P.; Dennis, J.J. -
Skin Immunity to Candida Albicans
TREIMM 1284 No. of Pages 11 Feature Review Skin Immunity to Candida albicans Sakeen W. Kashem1 and Daniel H. Kaplan2,* Candida albicans is a dimorphic commensal fungus that colonizes healthy Trends human skin, mucosa, and the reproductive tract. C. albicans is also a predomi- Primary immunodeficiencies reveal nantly opportunistic fungal pathogen, leading to disease manifestations such as conserved IL-17 stimulating/signaling disseminated candidiasis and chronic mucocutaneous candidiasis (CMC). The pathways involved in mucocutaneous differing host susceptibilities for the sites of C. albicans infection have revealed defense against C. albicans. tissue compartmentalization with tailoring of immune responses based on the Mouse models have demonstrated site of infection. Furthermore, extensive studies of host genetics in rare cases of both innate and adaptive sources of IL-17 in response to C. albicans. CMC have identified conserved genetic pathways involved in immune recogni- tion and the response to the extracellular pathogen. We focus here on human Immunity against C. albicans is com- and mouse skin as a site of C. albicans infection, and we review established and partmentalized towards sites of infection. newly discovered insights into the cellular pathways that promote cutaneous antifungal immunity. Non-hematopoietic cells provide anti- fungal immunity in the skin. Compartmentalization of Immunity Against C. albicans Skin Infection C. albicans is the most common and well-studied of the disease-causing Candida spp., and naturally colonizes the skin, genital, and/or intestinal mucosa in up to 70% of healthy individuals [1]. Under normal circumstances, the fungus does not cause disease but the absence of appropriate immune recognition and response mechanisms can lead to the inability to control C.